



Order ID 739810
 Provider Exagen Provider MD

Specimen	Patient	Sample, Susan S
Collected 01/15/2022		
Received 01/16/2022	Gender - DOB Female - 01/01/1996	
Test Order	Identifier Received	
Created 01/16/2022		
Reported 01/20/2022	Exagen ID	541163

AVISE SLE Prognostic Test Report

Analyte	Value	Interpretation	Reference Range
+ Anti-C1q IgG	90.0 Units	POSITIVE	<20 - Negative ≥20 - Positive
Anti-Ribosomal P IgG	8.00 Units	Negative	<20 - Negative ≥20 - Positive
+ Anti-Phosphatidylserine/Prothrombin IgM *	45.00 Units	POSITIVE	≤30 – Negative >30 – Positive
+ Anti-Phosphatidylserine/Prothrombin IgG *	34.00 Units	POSITIVE	≤30 – Negative >30 – Positive
Anti-Cardiolipin IgM *	2.0 U/mL	Negative	<10 – Negative 10-40 – Weak Positive >40 – Positive
Anti-Cardiolipin IgG *	4.0 U/mL	Negative	<10 – Negative 10-40 – Weak Positive >40 – Positive
Anti-Cardiolipin IgA *	8.0 U/mL	Negative	<14 – Negative 14-20 – Equivocal >20 – Positive
Anti-β2 Glycoprotein 1 IgM *	3.0 U/mL	Negative	<7 – Negative 7-10 – Equivocal >10 – Positive
Anti-β2 Glycoprotein 1 IgG *	2.0 U/mL	Negative	<7 – Negative 7-10 – Equivocal >10 – Positive
Anti-β2 Glycoprotein 1 IgA *	5.0 U/mL	Negative	<7 – Negative 7-10 – Equivocal >10 – Positive

*Analyte was also reported on the AVISE Lupus/CTD and/or AVISE APS report(s)—results for these analytes are restated in this report

Test Method Description

Results were obtained by enzyme-linked immunosorbent (ELISA) for the quantitative determination of Anti-C1q IgG, Anti-Ribosomal P IgG and Anti-Phosphatidylserine/Prothrombin (PS/PT) antibodies (IgM and IgG). Antibodies against cardiolipin (IgM, IgG, IgA) and β2-glycoprotein I (IgM, IgG, IgA) were determined using Enzyme Linked Fluorescent Immunoassay.

References

1. INOVA Markers references and results (INOVA product inserts).
2. Yin et al. Lupus. 2012 Sep;21(10):1088-97. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis.
3. Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2011 Oct;20(12):1267-74. doi: 10.1177/0961203311411597. Epub 2011 Aug 3.
4. Hanly et al. Ann Rheum Dis. 2011 Oct;70(10):1726-32. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.
5. Akhter et al. J Rheumatol. 2013 Mar;40(3):282-6. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus.



1261 Liberty Way, Vista CA 92081
 CLIA# 05D1075048
 CAP# 7201051 | NYSDOH PFI# 8369

Laboratory Directors:
 Richard Safrin, MD
 R. Harper Summers, MD

Provider Relations: 888.452.1522

AVISE and the AVISE and Exagen logos are registered trademarks of Exagen Inc. ©2022 All Rights Reserved

This test is used for clinical purposes, though results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. It should not be regarded as investigational or for research. It has not been cleared or approved by the FDA. Exagen is regulated under CLIA as qualified to perform high-complexity testing. SA1060 (2/22)